Latest News and Press Releases

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

BOSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion...

Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need Praxis to receive upfront proceeds of...

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsi

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...

Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for...